United States SEC Fines Biotech Company Zymergen $30 Million for Misleading IPO Investors Including on Products & Revenue, Raised $530 Million in 2021 IPO & Filed for Bankruptcy in 2023
15th September 2024 | Hong Kong
The United States Securities and Exchange Commission (SEC) has fined biotech company Zymergen $30 million for misleading IPO investors including on products & revenue, raising $530 million in the 2021 IPO and filed for bankruptcy in 2023. United States SEC (13/9/24): “The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its IPO in April 2021 and filed for bankruptcy in 2023. Zymergen agreed to pay a $30 million civil penalty to resolve the SEC’s charges. According to the SEC’s order, Zymergen claimed that it had a $1 billion electronics display market opportunity for Hyaline, but the estimate was based on flawed and unreasonable assumptions that included product markets that were poor fits for Hyaline’s technical characteristics and unsupported premium pricing. The SEC’s order also finds that Zymergen provided misleading revenue forecasts to research analysts that far exceeded internal estimates. Additionally, the order finds that Zymergen misled investors during its first public earnings call by misrepresenting the status of Hyaline’s customer pipeline while omitting significant technical and commercial problems facing the product. The SEC’s order finds that Zymergen violated certain antifraud provisions of the federal securities laws. Without admitting or denying the SEC’s findings, and subject to bankruptcy court approval, Zymergen agreed to a cease-and-desist order and to pay the civil penalty referenced above.”
“ United States SEC Fines Biotech Company Zymergen $30 Million for Misleading IPO Investors Including on Products & Revenue, Raised $530 Million in 2021 IPO & Filed for Bankruptcy in 2023 “
United States SEC Fines Biotech Company Zymergen $30 Million for Misleading IPO Investors Including on Products & Revenue, Raised $530 Million in 2021 IPO & Filed for Bankruptcy in 2023
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2024 Investment Day
- March 2024 - Hong Kong
- March 2024 - Singapore
- July 2024 - Hong Kong
- July 2024 - Singapore
- Sept 2024 - Hong Kong
- Sept 2024 - Singapore
- Oct 2024 - Hong Kong
- Nov 2024 - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
